Completed PHASE3 INTERVENTIONAL 3-arm NCT00381953

High-dose IFN and PEG IFN for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV

A Comparative Study of High-dose Interferon Alfa-2a and Pegylated Interferon Alfa-2a for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV

Sponsor: Foundation for Liver Research

Conditions Hepatitis C

Interventions Interferon alfa-2a Peginterferon alfa-2a Ribavirin

Updated 7 times since 2017 Last updated: Aug 26, 2021 Started: Feb 28, 2003 Primary completion: Apr 30, 2006 Completion: Jul 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00381953, this PHASE3 trial focuses on Hepatitis C and remains completed. Sponsored by Foundation for Liver Research, it has been updated 7 times since 2003, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Oct 2021 — Jul 2024 [monthly]

Completed PHASE3
Sep 2021 — Oct 2021 [monthly]

Completed PHASE3
Jan 2021 — Sep 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Feb 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Foundation for Liver Research

Data source: Foundation for Liver Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rotterdam, Netherlands